. Moreover, sampling points are generally chosen arbitrarily or sometimes by using more sophisticated approaches like sensitivity functions or stepwise linear regression (Ratain & Vogelzang, 1987) . But these approaches are not optimal, since they do not provide maximal precision in model parameters.
Pharmacokinetic population studies have been developed in recent years to describe intra-and interindividual variabilities (Sheiner & Beal, 1981a) . Among the available methods. Bayesian estimation (BE) allows satisfactory model parameter estimation with a limited number of sampling points and thus reduces hospitalisation time as well as cost of pharmacokinetic studies (Sheiner et al., 1979) . Such methodological schemes associating BE with a population study have been performed for several drugs (D'Argenio & Khakmahd, 1983; Lacarelle et al., 1987; Vozeh & Steiner. 1987; Serre-Debeauvais et al., 1987) but few anticancer ones (Iliadis et al., 1985; Favre et al., 1987) . Moreover, sampling points are generally chosen arbitrarily or sometimes by using more sophisticated approaches like sensitivity functions or stepwise linear regression (Ratain & Vogelzang, 1987) . But these approaches are not optimal, since they do not provide maximal precision in model parameters. Adriamycin (ADM) is a broad-spectrum antineoplastic drug which is active against a wide variety of tumours.
Experimental studies have suggested that ADM concentration-time product (area under the curve, AUC) is a determinant factor for tumour cell lethality (Eichholtz-Wirth, 1980; Ritch et al., 1982) . Robert et al. (1982) after the start of injection. As all patients were treated on an outpatient basis, it was not possible to get blood samples for more than the 24 h. From these patients and their cycles, 41 concentration-time curves were obtained. Blood samples were collected in EDTA tubes and immediately centrifuged.
Plasma was stored at -20-C until analysis (within 2 weeks). ADM was quantified by HPLC. Extraction was performed on Sep-Pak C18 cartnrdges (Millipore, Waters) as previously described (Robert. 1980 ) with slight modifications: cartnrdges were conditioned by successive elutions with 2ml methanol and 5 ml phosphate buffer (Na2HPO4, 0.05 M; NaH2P04, 0.05 M; 2:1). One ml of plasma (patient or plasma for standard curve) spiked with 50 pi of internal standard (daunorubicin, 1 nmol ml -1) was passed through the cartridge, followed by I ml of phosphate buffer (discarded). Drug material was eluted by 3 ml of methanol in previously siliconated tubes. After drying (N2, 40-C), the residue was diluted in 250pd of HPLC bufter, centrifuged for 10 min at 4 C, and injected into the HPLC system. Analysis was performed on an HPLC column pBondapak phenyl 30 mm x 0.4 mm ID (Millipore, Waters) with a CH3CN-formiate buffer (33.5/66.5), pH 4, at a flow rate of 2.5 ml min-I-Fluorescent detection was performed with a spectrofluorimeter (Kontron SFM 25) (Sheiner & Beal, 1985) . The initial set of 41 cycles (25 patients) was randomly divided into two groups: one including 15 cycles (10 patients, group I) was used to calculate population characteristics by the standard two-stage method (Sheiner & Beal, 1981a) . Inter-and intra-individual variabilities are both present in population studies; in order to express the former, we randomly chose 10 subjects and, to express the latter, five additional courses were drawn in four of these 10 subjects. This was done to take into account changes in the pharmacokinetic behaviour between two successive courses, e.g. a possible time-dependence. The other group of 26 cycles (17 subjects, group II) was used as a test data set to evaluate the performance of BE associated with a reduced sampling protocol.
First, population data allowed computation of an optimal sampling time set to be used for all patients of group II. For ethical reasons and improved patient comfort, we planned only two sampling points, at least 5 min apart, during the 24 h following the ADM administration. This calculation was performed on the basis of D-optimality theory. Its main characteristic is to guarantee a precise estimation of the model pharmacokinetic parameters (the macroconstants) by optimising a non-linear cost function (Bard, 1974;  Launay & Iliadis, 1988) . The criterion value, i.e. the maximised cost function value, is inversely proportional to the volume of the confidence region for the parameter estimates (Atkinson & Hunter, 1968) ; the higher its value is, the smaller the volume is and the more precise the estimates are.
In fact, the set of two optimal samplnig times yielded by the D-optimality criterion remains theoretical because these times differ from the experimental ones. Thus, to choose the available experimental sampling times closest to the theoretical ones, we compared the D-optimality criterion values obtained for all experimental two time-point combinations.
Secondly, as population data are a priori information on the ADM pharmacokinetic behaviour, they are used in the BE criterion performed on the test data set (Iliadis et al., 1985) . All MLE and BE as well as optimal design calculations were performed on a desktop computer (Tektronix 4052) using APIS software (Iliadis, 1985; Launay & Iliadis, 1988) . The parameters identified by MLE and BE are the macroconstants from which Cl is computed (Wagner, 1975 Resuhts ADM population data describing the mean behaviour (mean parameters), interindividual variability (covariance and correlation matrix) and residual intra-individual variability (coefficient of variation of residual variability) are presented in Table I . Because of the low residual variability (15%) and its measurement error (10%), two compartment modelling is a good description of the observed data. The coefficient of variation of the exponents (a and b) was smaller than that of the coefficients (A and B), indicating a low interindividual variability for the slopes of the two phases. The low correlation coefficients expressing covariances indicate that there is no preferential relation between parameters. Figure I shows the mean kinetic profile of ADM after a 20mg bolus injection with its 68.3% confidence intervals expressing interindividual variability of concentrations in function of time.
Design optimisation with population data provided the two 'theoretical' time points located at 26 min and 24 h, corresponding to a critenron value of 35.743. Computation of The macroconstants are the model parameters: A and B are the coefficients and a and b are the exponents. The covanrance-correlation matrix is divided into three parts: the correlations between two parameters are in the upper triangle (1). They were computed from the covariances which are written in the lower triangle (2). The variance of each parameter (squared standard deviation) is presented on the diagonal of the matrix (3). (-1.26, 4.98) and (5.19, 9.79) respectively. We concluded that bias was not significantly different from zero (its confidence interval includes zero) and the positive sign indicates that BE Cl is overestimated by about 1.861h-1. The overestimation is not significant. We noted also that precision of Cl estimates was low with respect to the dispersion of Cl values in the population: the standard deviation of BE Cl expressing interindividual variability, computed on group II data, reached 29.851h-1. Thus the ratio of this dispersion to the precision of BE Cl estimation is 0.262; this means that the Bayesian procedure is discriminative enough to distinguish subjects within members of the same population. Figure 2 (Ratain & Vogelzang, 1987) . More recently, this team carried out the same kind of study with amonafide (Ratain et al., 1988 
